| Date Filed | Type | Description |
| 01/03/2018 |
SC 13G/A
| SABBY MANAGEMENT, LLC reports a 2.7% stake in Arno Therapeutics, Inc. |
| 04/03/2017 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 04/03/2017 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 03/30/2017 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)] |
| 03/28/2017 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 03/28/2017 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement |
| 03/28/2017 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement |
| 03/28/2017 |
BW
| Arno Therapeutics Announces Plan to Deregister its Common Stock |
| 02/14/2017 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2017 |
SC 13G/A
| Opko Health, Inc. reports a 8.8% stake in Arno Therapeutics, Inc. |
| 02/14/2017 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/09/2017 |
SC 13D
| Zucker Jonathan J reports a 14.7% stake in Arno Therapeutics, Inc. |
| 01/05/2017 |
SC 13G/A
| SABBY MANAGEMENT, LLC reports a 10% stake in Arno Therapeutics, Inc. |
| 01/03/2017 |
SC 13D/A
| Ruchefsky Steven B reports a 2.2% stake in Arno Therapeutics, Inc. |
| 11/18/2016 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 11/14/2016 |
10-Q
| Quarterly Report for the period ended September 30, 2016 |
| 11/04/2016 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements |
| 11/04/2016 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 11/03/2016 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 10/12/2016 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 09/08/2016 |
SC 13D
| Belldegrun Arie reports a 15.9% stake in Arno Therapeutics, Inc. |
| 09/08/2016 |
SC 13D
| Ruchefsky Steven B reports a 17.7% stake in Arno Therapeutics, Inc. |
| 09/08/2016 |
SC 13D
| Kariv Tomer reports a 12.4% stake in Arno Therapeutics, Inc. |
| 08/30/2016 |
D
| Form D - Notice of Exempt Offering of Securities |
| 08/22/2016 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 08/22/2016 |
10-Q
| Quarterly Report for the period ended June 30, 2016 |
| 08/16/2016 |
8-K
| Quarterly results |
| 08/16/2016 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB |
| 05/16/2016 |
10-Q
| Quarterly Report for the period ended March 31, 2016 |
| 04/19/2016 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 04/19/2016 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 04/01/2016 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933 [Amend] |
| 03/30/2016 |
10-K
| Annual Report for the period ended December 31, 2015 |
| 03/17/2016 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|